Mangoceuticals shares surge 71.60% after-hours after lawsuit against Clarity and in-house platform development.

Mangoceuticals, Inc. (NASDAQ:MGRX) surged 71.60% in after-hours trading, driven by renewed investor interest amid a legal dispute with Clarity Ventures and strategic operational improvements. The stock’s volatility followed a 54.51% decline on Friday, but recent developments highlighted its resilience. The lawsuit against Clarity Ventures, alleging failure to deliver a HIPAA-compliant platform, prompted Mangoceuticals to develop an in-house telehealth and e-commerce system, which the company claims enhanced customer acquisition and order execution. Additionally, the TRT (testosterone replacement therapy) program under its MangoRx brand reported a 336% monthly sales increase, with lower customer acquisition costs, positioning TRT as a key growth driver. These operational pivots and product advancements, alongside a global patent filing for its antiviral technology, likely fueled the after-hours rally despite the ongoing litigation.